C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE
B 细胞系中的 C-MYC 表达和凋亡
基本信息
- 批准号:2089092
- 负责人:
- 金额:$ 19.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1984
- 资助国家:美国
- 起止时间:1984-01-01 至 1997-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Apoptosis or programmed cell death (PCD) is a general mechanism of cell
suicide that has been implicated in tolerization of B lymphocytes. For
example, treatment of the murine early B lymphoma WEHI 231 line, a model
for study of B cell tolerance, with an antiserum against its expressed
surface IgM, such as goat anti-mouse Ig (GaMIg) or anti-mu antisera,
inhibits its proliferation via apoptosis. Oligosomal degradation of DNA
is detectable by 12 hours post-GaMIg treatment. Recent evidence has
demonstrated that the expression of the nuclear proto-oncogene c-myc is
necessary for PCD, promoting apoptosis in a dose-dependent fashion. Here
the role of c-myc in apoptosis will be explored using the WEHI 231 line
as model system. The expression of c-myc in WEHI 231 cells and the
effects of apoptosis have been extensively characterized by ongoing work
from the PI's and other laboratories. Treatment of WEHI 231 cells with
GaMIg results in an initial increase in expression of c-myc RNA of 5- to
10-fold by 1-2 hours, which is followed by a dramatic decline by 4-6
hours post-treatment. The synthesis of c-myc protein parallels the early
changes in RNA levels; furthermore, the protein is transiently
hyperphosphorylated at 1 hour. By 24 hours, mRNA and protein levels are
well below those observed in control cells. A major site of control of
these changes in c-myc RNA expression is mediated at the transcription
level. The increase in c-myc expression appears to be critical for
apoptosis. For example, the PI's laboratory has recently shown that
treatment with an anti-delta antiserum of a WEHI 231 line stably
transfected with a delta heavy chain (WEHI 231-delta), which fails to
induce apoptosis, failed to induce c-myc protein levels, in contrast to
treatment with anti-mu serum. Thus the aims of this proposal are to 1)
measure the effects of anti-Ig treatment on c-myc protein expression, and
2) characterize the transcription factors mediating the changes in c-myc
RNA levels; particular emphasis, will be placed on the nuclear factor
NF-KB, which the PI's laboratory has demonstrated plays a major role in
regulation of c-myc transcription. Specifically, post-translational
modifications and association of c-myc with other cellular proteins will
be examined. The biochemical nature and functional effects of changes in
expression of NF-KB, noted during apoptosis, will be measured. Results
will be correlated with apoptosis through use of the WEHI 231-delta line.
These studies should provide important insights into the control of
apoptosis in lymphocytes, the development of B cell tolerance and the
role of the c-myc oncogene in these processes.
细胞凋亡或程序性细胞死亡(PCD)是细胞凋亡的一般机制。
与B淋巴细胞耐受有关的自杀。 为
例如,治疗小鼠早期B淋巴瘤WEHI 231系,一种模型
为研究B细胞耐受性,用抗其表达的抗血清,
表面IgM,例如山羊抗小鼠IG(加米格)或抗μ抗血清,
通过凋亡抑制其增殖。 DNA的寡聚体降解
在GaMIg处理后12小时可检测到。 最近的证据
证明了核原癌基因c-myc的表达是
这是PCD所必需的,以剂量依赖性方式促进凋亡。 这里
利用WEHI 231细胞系探讨c-myc在细胞凋亡中的作用
作为模型系统。 c-myc在WEHI 231细胞中的表达及其与细胞凋亡的关系
细胞凋亡的影响已经被正在进行的工作广泛地表征,
从私家侦探和其他实验室拿来的 用以下物质处理WEHI 231细胞:
加米格导致c-myc RNA表达的初始增加5- 10倍。
10-1-2小时,随后急剧下降4-6倍
治疗后3小时。 c-myc蛋白的合成与早期的
RNA水平的变化;此外,蛋白质是瞬时的
在1小时时过度磷酸化。 到24小时,mRNA和蛋白质水平
远低于在对照细胞中观察到的那些。 一个主要的控制点,
c-myc RNA表达的这些变化是在转录时介导的,
水平 c-myc表达的增加似乎是至关重要的,
凋亡 例如,PI的实验室最近表明,
用WEHI 231系的抗δ抗血清稳定处理
用δ重链(WEHI 231-δ)转染,其不能
诱导细胞凋亡,不能诱导c-myc蛋白水平,与
抗mu血清治疗。 因此,本提案的目的是:1)
测量抗Ig处理对c-myc蛋白表达的影响,和
2)鉴定介导c-myc变化的转录因子
RNA水平;特别强调,将放在核因子
NF-κ B,PI的实验室已经证明了在
c-myc转录的调控。 特别是翻译后
c-myc与其它细胞蛋白的修饰和结合将
接受检查。 变化的生物化学性质和功能效应
将测量在细胞凋亡期间记录的NF-κ B的表达。 结果
将通过使用WEHI 231-δ系与细胞凋亡相关。
这些研究应该为控制
淋巴细胞凋亡、B细胞耐受性的发展以及
c-myc癌基因在这些过程中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GAIL E. SONENSHEIN其他文献
GAIL E. SONENSHEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GAIL E. SONENSHEIN', 18)}}的其他基金
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers
开发用于检测 ADAM8 阳性癌症的伴随诊断测定法
- 批准号:
10685491 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers
开发用于检测 ADAM8 阳性癌症的伴随诊断测定法
- 批准号:
10545124 - 财政年份:2022
- 资助金额:
$ 19.96万 - 项目类别:
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
ADAM8 抗体靶向治疗三阴性乳腺癌
- 批准号:
9984632 - 财政年份:2016
- 资助金额:
$ 19.96万 - 项目类别:
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
ADAM8 抗体靶向治疗三阴性乳腺癌
- 批准号:
9047902 - 财政年份:2016
- 资助金额:
$ 19.96万 - 项目类别:
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
ADAM8 抗体靶向治疗三阴性乳腺癌
- 批准号:
9353930 - 财政年份:2016
- 资助金额:
$ 19.96万 - 项目类别:
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor
赖氨酰氧化酶前肽:乳腺癌抑制剂
- 批准号:
8610255 - 财政年份:2010
- 资助金额:
$ 19.96万 - 项目类别:
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor
赖氨酰氧化酶前肽:乳腺癌抑制剂
- 批准号:
8059659 - 财政年份:2010
- 资助金额:
$ 19.96万 - 项目类别:
Research Project 3: Role of the NF-kB/Rel in Mammary Carcinogenesis
研究项目3:NF-kB/Rel在乳腺癌发生中的作用
- 批准号:
8143313 - 财政年份:2010
- 资助金额:
$ 19.96万 - 项目类别:
Lysyl Oxidase Propeptide: Breast Cancer Inhibitor
赖氨酰氧化酶前肽:乳腺癌抑制剂
- 批准号:
7767218 - 财政年份:2010
- 资助金额:
$ 19.96万 - 项目类别:
相似海外基金
Targeting pathogenic TAR DNA-binding protein 43 to treat frontotemporal dementia and motor neuron disease
靶向致病性 TAR DNA 结合蛋白 43 治疗额颞叶痴呆和运动神经元疾病
- 批准号:
nhmrc : 2001572 - 财政年份:2021
- 资助金额:
$ 19.96万 - 项目类别:
Ideas Grants
Electron microscopic analysis of a G4 DNA-binding protein Rif1, a key organizer of chromosomal domains
G4 DNA 结合蛋白 Rif1(染色体结构域的关键组织者)的电子显微镜分析
- 批准号:
18K06102 - 财政年份:2018
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional analysis of methylated DNA-binding protein CIBZ in mouse embryogenesis
甲基化DNA结合蛋白CIBZ在小鼠胚胎发生中的功能分析
- 批准号:
16K08587 - 财政年份:2016
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Continuous directed evolution of a light-controlled DNA-binding protein
光控DNA结合蛋白的连续定向进化
- 批准号:
437922-2013 - 财政年份:2015
- 资助金额:
$ 19.96万 - 项目类别:
Postgraduate Scholarships - Doctoral
Function and evolution of mitochondrial DNA-binding protein in the fission yeast
裂殖酵母线粒体DNA结合蛋白的功能和进化
- 批准号:
15K07168 - 财政年份:2015
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a photo-controlled DNA-binding protein
光控 DNA 结合蛋白的开发
- 批准号:
459937-2014 - 财政年份:2015
- 资助金额:
$ 19.96万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Functional analysis of the single-stranded DNA-binding protein FUBP1 as a transcriptional regulator of hematopoietic stem cell self-renewal
单链DNA结合蛋白FUBP1作为造血干细胞自我更新转录调节因子的功能分析
- 批准号:
276833671 - 财政年份:2015
- 资助金额:
$ 19.96万 - 项目类别:
Research Grants
Continuous directed evolution of a light-controlled DNA-binding protein
光控DNA结合蛋白的连续定向进化
- 批准号:
437922-2013 - 财政年份:2014
- 资助金额:
$ 19.96万 - 项目类别:
Postgraduate Scholarships - Doctoral
Structural ans functional analysis of single-stranded DNA-binding protein DdrA
单链 DNA 结合蛋白 DdrA 的结构和功能分析
- 批准号:
26506030 - 财政年份:2014
- 资助金额:
$ 19.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a photo-controlled DNA-binding protein
光控 DNA 结合蛋白的开发
- 批准号:
459937-2014 - 财政年份:2014
- 资助金额:
$ 19.96万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral